Link Securities | Grifols (GRF) plans to make an early repayment of €500 million of its 7.5% senior secured bonds maturing in 2030. This transaction would enable the company to reduce its higher-cost debt, as part of its strategy to lower its cash interest expense and strengthen its capital structure. The partial repayment of the 7.5% senior secured bonds maturing in 2030 will take place following the previously announced and…

Banc Sabadell | Following the deaths of two customers who visited a Grifols (GRF) plasma centre in Canada, there are calls for the closure of the company’s centres there, according to Bloomberg. A third person is reportedly suing Grifols for liver damage, and the Canadian health service has reportedly stated that there are at least four Grifols centres in the country that do not meet medical standards. Assessment: Negative news…

Link Securities | The company has received financing commitments from a syndicate of international banks for a new revolving credit facility (RCF) of approximately $2 billion, the website Bolsamania.com reported yesterday. This new credit facility would more than double the size of the previous one, which stood at $938 million, and would have a maturity of 6.5 years, further strengthening Grifols’ financial flexibility and balance sheet. The new facility coming…

Link Securities | On Monday, credit rating agency Moody’s Ratings upgradedGrifols’ corporate family rating (CFR) from ‘B2’ to “B1”, reflecting the company’s continued operating performance and the ‘strength’ of its business fundamentals, Bolsamania.com reported yesterday. On the other hand, the agency has changed the outlook from ‘positive’ to ‘stable’. The rating agency explained that this change in rating reflects Grifols’ ‘solid operating performance, with strong revenue growth and profitability, which…

Link Securities | Spanish pharmaceutical company Grifols (GRF) reported on Tuesday that on 11 December 2025, the European Medicines Agency (EMA) had issued a Certificate of Compliance with EU legislation for plasma supplied by Grifols Egypt for Plasma Derivatives (GEPD), the joint venture established in 2020 between Grifols and Egypt’s National Service Projects Organisation. This certification was granted following a quality inspection of the plasma centres owned by GEPD and…

Alphavalue/Divacons | Gotham City Research believes that the legal investigations stemming from its bearish attack on Grifols (GRF) in January 2024 will not result in a significant financial blow to the company, and has therefore ruled out making provisions for this possible contingency. This position is maintained despite the fact that the Spanish pharmaceutical company has initiated legal proceedings in the United States in which it is claiming millions in…

Alphavalue / Divacons | The Catalan company specialising in blood products is stepping up its legal offensive against Gotham City Research and has asked Court No. 4 of the National Court for the two KPMG partners who signed the 2021-2023 audits to testify in the case. The pharmaceutical company is seeking to strengthen its defence after the bearish attack that cost it around €9 million in January 2024. The Institute…